ORIENT-32
Regimen
- Experimental
- sintilimab + IBI305 (bevacizumab biosimilar)
- Control
- sorafenib
Population
HBV-associated unresectable or metastatic hepatocellular carcinoma in China, no prior systemic therapy
Key finding
Interim mOS NR vs 10.4 mo (HR 0.57, 95% CI 0.43-0.75, p<0.0001); mPFS 4.6 vs 2.8 mo (HR 0.56, p<0.0001); etiology: **HBV >93%** (China-only cohort, design specified HBV-associated HCC); 6 vs 2 treatment-related deaths
Source: PMID 34143971